Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Bladder Cancer

Free Subscription 01.10.2018 1 Adv Exp Med Biol 1 Asian Pac J Cancer Prev 1 Basic Clin Pharmacol Toxicol 3 Biomed Pharmacother 1 BJU Int 1 BMC Urol 1 Bull Cancer 1 Cancer Immunol Immunother 1 Cancer Med 1 Clin Cancer Res 1 Cochrane Database Syst Rev 1 Comput Methods Programs Biomed 1 Diagn Cytopathol 2 Eur Urol 1 Eur Urol Focus 1 Exp Cell Res 1 Fetal Pediatr Pathol 1 Front Oncol 1 Int Urol Nephrol 2 J Cancer Res Ther 1 J Cell Mol Med 1 Jpn J Clin Oncol 1 Methods Inf Med 1 Mol Cancer Ther 1 Nat Rev Urol 1 Nutrients 1 PLoS One 1 Sci Rep 1 Surg Infect (Larchmt) 1 Urol Int 2 Urologiia 3 World J Urol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Adv Exp Med Biol

1. KRAJEWSKI W, Halska U, Poletajew S, Piszczek R, et al
   Influence of Transurethral Resection of Bladder Cancer on Sexual Function, Anxiety, and Depression.
   Adv Exp Med Biol. 2018 Sep 23. doi: 10.1007/5584_2018.
   PubMed     Text format     Abstract available
   
   

   
   Asian Pac J Cancer Prev

2. BUDAK DILER S, Aybuga F
   Association of Autophagy Gene ATG16L1 Polymorphism with Human Prostate Cancer and Bladder Cancer in Turkish Population
   Asian Pac J Cancer Prev. 2018;19:2625-2630.
   PubMed     Text format     Abstract available
   
   

   
   Basic Clin Pharmacol Toxicol

3. HALLAS J, Margulis AV, Pottegard A, Kristiansen NS, et al
   Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.
   Basic Clin Pharmacol Toxicol. 2018;122:612-619.
   PubMed     Text format     Abstract available
   
   

   
   Biomed Pharmacother

4. JIANG B, Hailong S, Yuan J, Zhao H, et al
   Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis.
   Biomed Pharmacother. 2018;108:500-507.
   PubMed     Text format     Abstract available
   
   
5. JIANG L, Song H, Guo H, Wang C, et al
   Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106.
   Biomed Pharmacother. 2018;107:1583-1590.
   PubMed     Text format     Abstract available
   
   
6. MAO MH, Huang HB, Zhang XL, Li K, et al
   Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
   Biomed Pharmacother. 2018;107:1093-1103.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

7. SUAREZ-IBARROLA R, Soria F, Abufaraj M, D'Andrea D, et al
   Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor.
   BJU Int. 2018 Sep 24. doi: 10.1111/bju.14557.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

8. YE J, Zhang Y, Cai Z, Jiang M, et al
   Increased expression of immediate early response gene 3 protein promotes aggressive progression and predicts poor prognosis in human bladder cancer.
   BMC Urol. 2018;18:82.
   PubMed     Text format     Abstract available
   
   

   
   Bull Cancer

9. MA G, Yang X, Liang Y, Wang L, et al
   Precision medicine and bladder cancer heterogeneity.
   Bull Cancer. 2018 Sep 19. pii: S0007-4551(18)30237.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Immunol Immunother

10. JIANG Q, Fu Q, Chang Y, Liu Z, et al
    CD19(+) tumor-infiltrating B-cells prime CD4(+) T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2018 Sep 26. pii: 10.1007/s00262-018-2250.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Med

11. MA W, Ma J, Ma P, Lei T, et al
    Targeting immunotherapy for bladder cancer using anti-CD3x B7-H3 bispecific antibody.
    Cancer Med. 2018 Sep 25. doi: 10.1002/cam4.1775.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

12. RUBIO C, Martinez-Fernandez M, Segovia C, Lodewijk I, et al
    Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status.
    Clin Cancer Res. 2018 Sep 21. pii: 1078-0432.CCR-18-0685.
    PubMed     Text format     Abstract available
    
    

    
    Cochrane Database Syst Rev

13. NARAYAN V, Kahlmeyer A, Dahm P, Skoetz N, et al
    Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Cochrane Database Syst Rev. 2018;7:CD012838.
    PubMed     Text format     Abstract available
    
    

    
    Comput Methods Programs Biomed

14. LOPEZ-FERNANDEZ H, Araujo JE, Jorge S, Glez-Pena D, et al
    S2P: A software tool to quickly carry out reproducible biomedical research projects involving 2D-gel and MALDI-TOF MS protein data.
    Comput Methods Programs Biomed. 2018;155:1-9.
    PubMed     Text format     Abstract available
    
    

    
    Diagn Cytopathol

15. RENSHAW AA, Gould EW
    Evidence-based adequacy criteria for instrumented urine cytology using cytospin preparations.
    Diagn Cytopathol. 2018;46:520-521.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

16. TEOH JYC, Herrmann TRW, Babjuk M
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30657.
    PubMed     Text format    
    
    
17. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30663.
    PubMed     Text format    
    
    

    
    Eur Urol Focus

18. BLACK P
    Critical Questions To Optimize Intravesical Therapy for Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Sep 24. pii: S2405-4569(18)30258.
    PubMed     Text format    
    
    

    
    Exp Cell Res

19. ZHANG W, Feng H, Chen Q, Lu X, et al
    The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer.
    Exp Cell Res. 2018 Sep 19. pii: S0014-4827(18)30960.
    PubMed     Text format     Abstract available
    
    

    
    Fetal Pediatr Pathol

20. LANG A, Dehner LP
    Delayed Metastasis of Clear Cell Sarcoma of Kidney to Bladder After 7 Disease-Free Years.
    Fetal Pediatr Pathol. 2018;37:126-133.
    PubMed     Text format     Abstract available
    
    

    
    Front Oncol

21. SANTONI G, Morelli MB, Amantini C, Battelli N, et al
    Urinary Markers in Bladder Cancer: An Update.
    Front Oncol. 2018;8:362.
    PubMed     Text format     Abstract available
    
    

    
    Int Urol Nephrol

22. WASEN C, Ekstrand M, Levin M, Giglio D, et al
    Epidermal growth factor receptor function in the human urothelium.
    Int Urol Nephrol. 2018;50:647-656.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Ther

23. ZHU Q, Hong B, Zhang L, Wang J, et al
    Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway.
    J Cancer Res Ther. 2018;14.
    PubMed     Text format     Abstract available
    
    
24. LI Y, Cai B, Chen S, Fu X, et al
    Overexpression of Tat-interacting protein 30 inhibits the proliferation, migration, invasion and promotes apoptosis in bladder cancer cells.
    J Cancer Res Ther. 2018;14.
    PubMed     Text format     Abstract available
    
    

    
    J Cell Mol Med

25. DING M, Liu Y, Li J, Yao L, et al
    Oestrogen promotes tumorigenesis of bladder cancer by inducing the enhancer RNA-eGREB1.
    J Cell Mol Med. 2018 Sep 4. doi: 10.1111/jcmm.13861.
    PubMed     Text format     Abstract available
    
    

    
    Jpn J Clin Oncol

26. MATSUDA T, Niino M
    Bladder cancer incidence rates in the world from the Cancer Incidence in Five Continents XI.
    Jpn J Clin Oncol. 2018;48:953-954.
    PubMed     Text format    
    
    

    
    Methods Inf Med

27. TSAI TI, Zhang Y, Zhang Z, Chao GY, et al
    Considering Relationship of Proteins for Radiotherapy Prognosis of Bladder Cancer Cells in Small Data Set.
    Methods Inf Med. 2018;57:220-229.
    PubMed     Text format     Abstract available
    
    

    
    Mol Cancer Ther

28. TODENHOFER T, Seiler R, Stewart C, Moskalev I, et al
    Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer.
    Mol Cancer Ther. 2018 Sep 27. pii: 1535-7163.MCT-18-0107.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Urol

29. TAN WS, Kelly JD
    Intravesical device-assisted therapies for non-muscle-invasive bladder cancer.
    Nat Rev Urol. 2018 Sep 25. pii: 10.1038/s41585-018-0092.
    PubMed     Text format     Abstract available
    
    

    
    Nutrients

30. CHANG CP, Chan YY, Li CF, Chien LH, et al
    Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma.
    Nutrients. 2018;10.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

31. MURAI R, Itoh Y, Kageyama S, Nakayama M, et al
    Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens.
    PLoS One. 2018;13:e0204745.
    PubMed     Text format     Abstract available
    
    

    
    Sci Rep

32. WORST TS, Weis CA, Stohr R, Bertz S, et al
    CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
    Sci Rep. 2018;8:14383.
    PubMed     Text format     Abstract available
    
    

    
    Surg Infect (Larchmt)

33. KACZMAREK K, Leminski A, Bancarz A, Zakrzewska A, et al
    Post-Operative Infections among Patients Undergoing Radical Cystectomy at a Tertiary Center.
    Surg Infect (Larchmt). 2018;19:451-458.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

34. PALAZZETTI A, Bosio A, Dalmasso E, Destefanis P, et al
    De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
    Urol Int. 2018;100:185-192.
    PubMed     Text format     Abstract available
    
    

    
    Urologiia

35. ALYAEV YG, Rapoport LM, Vinarov AZ, Sorokin NI, et al
    [En-bloc laser resection of the urinary bladder tumor].
    Urologiia. 2018;:147-153.
    PubMed     Text format     Abstract available
    
    
36. ALYAEV YG, Dzeranov NK, Khokhlachev SB, Borisov VV, et al
    [A new method of evaluation of split renal function based on contrast-enhanced multislice spiral computed tomography].
    Urologiia. 2018;:26-33.
    PubMed     Text format     Abstract available
    
    

    
    World J Urol

37. VOSKUILEN CS, van de Putte EEF, der Hulst JB, van Werkhoven E, et al
    Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube.
    World J Urol. 2018;36:221-229.
    PubMed     Text format     Abstract available
    
    
38. ABUFARAJ M, Shariat SF, Foerster B, Pozo C, et al
    Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.
    World J Urol. 2018;36:231-240.
    PubMed     Text format     Abstract available
    
    
39. SORIA F, Krabbe LM, Todenhofer T, Dobruch J, et al
    Molecular markers in bladder cancer.
    World J Urol. 2018 Sep 26. pii: 10.1007/s00345-018-2503.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: